Since 2022, MEVAC partners with Kemin
Industries, a global leader in biotechnology
This partnership fuels our:
R&D Advancements: With Kemin’s scientific
expertise and resources.
Global Reach: Leveraging Kemin’s distribution
networks to expand into new markets.
Sustainability: Shared commitment to eco
friendly production and animal welfare
At MEVAC, we pioneer next-generation vaccine technologies with 2.5% of revenue at R&D investment to address
evolving global health challenges. Our innovative platforms combine scientific excellence with scalable
production to deliver safe,effective, and tailored solutions for animal and human health
In more than +42 countries and 4 continents worldwide.
At MEVAC, quality isn’t a promise—it’s a system.
We operate under GMP and ISO-certified protocols,
with full-spectrum control from raw materials to final dose.
Our vaccines undergo advanced testing in BSL2/BSL3 labs.
